SG11202005990RA - Process for providing pegylated protein composition - Google Patents
Process for providing pegylated protein compositionInfo
- Publication number
- SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA
- Authority
- SG
- Singapore
- Prior art keywords
- protein composition
- pegylated protein
- providing
- providing pegylated
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17211124 | 2017-12-29 | ||
| PCT/EP2018/097122 WO2019129876A1 (fr) | 2017-12-29 | 2018-12-28 | Procédé permettant d'obtenir une composition de protéine pegylée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005990RA true SG11202005990RA (en) | 2020-07-29 |
Family
ID=60954809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005990RA SG11202005990RA (en) | 2017-12-29 | 2018-12-28 | Process for providing pegylated protein composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200323993A1 (fr) |
| EP (1) | EP3731871B1 (fr) |
| JP (2) | JP7137625B2 (fr) |
| KR (1) | KR102523239B1 (fr) |
| CN (1) | CN111741770A (fr) |
| SG (1) | SG11202005990RA (fr) |
| WO (1) | WO2019129876A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111741770A (zh) * | 2017-12-29 | 2020-10-02 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE69027526T3 (de) | 1989-11-06 | 2005-03-24 | Cell Genesys, Inc., Foster City | Herstellung von proteinen mittels homologer rekombination |
| AU645294B2 (en) | 1989-12-22 | 1994-01-13 | Merck Serono Sa | Endogenous gene expression modification with regulatory element |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| CA2140002A1 (fr) | 1992-07-13 | 1994-01-20 | Jay Stout | Methode chimique pour la modification selective du groupement reactif au niveau du carbone-.alpha.de l'acide amine n- et/ou c-terminal d'un polypeptide de recombinant ou d'une portion de ce polypeptide |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| PT1157037E (pt) | 1999-01-29 | 2003-12-31 | Hoffmann La Roche | Conjugados de gcsf |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| WO2003000179A2 (fr) * | 2001-06-22 | 2003-01-03 | Pharmacia Corporation | Conjugues de proteine « progenipoietin » chimiquement modifies |
| ATE425767T1 (de) | 2002-12-19 | 2009-04-15 | Nektar Therapeutics Al Corp | Konjugate von cyanovirin-varianten und einem polyalkylenoxid |
| CA2577999A1 (fr) | 2004-08-31 | 2006-03-09 | Rory F. Finn | Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues |
| WO2007010552A2 (fr) * | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | Conjugue d'erythropoietine peg n-terminal |
| US20100075375A1 (en) * | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| CL2008002053A1 (es) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
| JP5765813B2 (ja) * | 2008-09-19 | 2015-08-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 治療用ペプチドのポリマーコンジュゲート |
| CN102639553A (zh) | 2009-11-24 | 2012-08-15 | 诺沃—诺迪斯克保健股份有限公司 | 纯化聚乙二醇化蛋白质的方法 |
| CA2808748C (fr) | 2010-09-14 | 2018-09-11 | Roberto Falkenstein | Procede pour purifier l'erythropoietine pegylee |
| CA2867609A1 (fr) * | 2012-03-16 | 2013-09-19 | Belrose Pharma, Inc. | Conjugues polymeres d'inhibiteurs de la c1-esterase |
| CN111741770A (zh) * | 2017-12-29 | 2020-10-02 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
| SG11202005952TA (en) * | 2017-12-29 | 2020-07-29 | Hoffmann La Roche | Process for providing pegylated protein composition |
-
2018
- 2018-12-28 CN CN201880089651.9A patent/CN111741770A/zh active Pending
- 2018-12-28 WO PCT/EP2018/097122 patent/WO2019129876A1/fr unknown
- 2018-12-28 SG SG11202005990RA patent/SG11202005990RA/en unknown
- 2018-12-28 US US16/957,462 patent/US20200323993A1/en active Pending
- 2018-12-28 EP EP18830890.2A patent/EP3731871B1/fr active Active
- 2018-12-28 JP JP2020536191A patent/JP7137625B2/ja active Active
- 2018-12-28 KR KR1020207021885A patent/KR102523239B1/ko active IP Right Grant
-
2022
- 2022-09-02 JP JP2022139645A patent/JP7541555B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102523239B1 (ko) | 2023-04-18 |
| JP2022169794A (ja) | 2022-11-09 |
| CN111741770A (zh) | 2020-10-02 |
| KR20200104380A (ko) | 2020-09-03 |
| EP3731871A1 (fr) | 2020-11-04 |
| JP7137625B2 (ja) | 2022-09-14 |
| US20200323993A1 (en) | 2020-10-15 |
| WO2019129876A1 (fr) | 2019-07-04 |
| EP3731871B1 (fr) | 2023-10-04 |
| EP3731871C0 (fr) | 2023-10-04 |
| JP7541555B2 (ja) | 2024-08-28 |
| JP2021508715A (ja) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249527A1 (zh) | Cd137特異性的蛋白 | |
| DK3445788T3 (en) | Novel bispecific polypeptides against cd137 | |
| IL288613A (en) | Multispecific proteins | |
| GB201502305D0 (en) | Protein | |
| GB201502306D0 (en) | Protein | |
| GB201503133D0 (en) | Chimeric protein | |
| SG11201704010UA (en) | Fibroin-derived protein composition | |
| ZA201708041B (en) | Novel proteins specific for lag-3 | |
| DK3737402T3 (en) | Modificeret protein | |
| GB201608197D0 (en) | Novel proteins | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| IL258570A (en) | Stable protein preparations | |
| EP3463414C0 (fr) | Interfaces de protéines | |
| EP3377633C0 (fr) | Production de protéines recombinantes | |
| GB201506223D0 (en) | Chimeric protein | |
| ZA201901862B (en) | Modified factor h binding protein | |
| GB201513033D0 (en) | Proteins | |
| GB2558968B (en) | G Proteins | |
| HK1257745A1 (zh) | 肽組合物 | |
| SG11202006140TA (en) | Process for providing pegylated protein composition | |
| ZA202003722B (en) | Modified globin proteins | |
| SG11202005990RA (en) | Process for providing pegylated protein composition | |
| SG11202005952TA (en) | Process for providing pegylated protein composition | |
| EP3505624A4 (fr) | Composition pour un anti-virus à arn comprenant une protéine eprs ou un fragment de celle-ci |